“醫(yī)學(xué)雙語閱讀：安全問題影響支架生產(chǎn)商”相信是準(zhǔn)備學(xué)習(xí)醫(yī)學(xué)英語的朋友比較關(guān)注的事情，為此，醫(yī)學(xué)教育網(wǎng)小編整理內(nèi)容如下：

stent makers hurt by reports about safety

安全報(bào)告打擊血管支架生產(chǎn)商

shareholder qualms about growth prospects for the$5 billion coronary stent business yesterday shook the stocks of boston scientific and johnson&johnson,the two leading stent makers.

昨天（9月7日），股東們的對(duì)心血管支架未來有五十億美元的增長(zhǎng)空間表示疑慮，這使兩家主要的血管支架生產(chǎn)商波士頓科技公司和強(qiáng)生制藥廠的股價(jià)產(chǎn)生了動(dòng)蕩。

shares of boston scientific fell 3.3 percent,or 57 cents,to$16.70.the stock of johnson&johnson,whose overall business is less dependent on stents,fell 46 cents,to$63.46.

波士頓科技公司的股票下跌了3.3%（57美分），達(dá)到了每股16.70美元。與波士頓科技公司相比，強(qiáng)生制藥廠的經(jīng)營(yíng)對(duì)血管支架業(yè)務(wù)的依賴性較小，其股價(jià)下降了46美分，降到每股63.46美元。

the declines came after a stream of reports about stent safety from a european medical meeting.those included the disclosure yesterday that boston scientific had quietly told federal regulators this summer that new analysis of the company's accumulating safety data found that patients using its best-selling taxus stent had a slightly greater but statistically clear risk of developing potentially deadly blood clots compared with older stent designs.

股票價(jià)格下跌是由于歐洲醫(yī)學(xué)會(huì)議的一系列關(guān)于血管支架安全方面的報(bào)道引起的。這也包括了昨天披露波士頓科技公司axus支架存在風(fēng)險(xiǎn)的報(bào)導(dǎo)。報(bào)道說，波士頓科技公司曾經(jīng)在今年夏天坦然地告訴聯(lián)邦調(diào)節(jié)員，根據(jù)公司累積安全數(shù)據(jù)分析顯示，與老的支架設(shè)

among the earlier reports at the meeting was a swiss study suggesting that in some patient groups the cypher stent of johnson&johnson posed even higher long-term clotting risks than taxus.

在會(huì)議早期的報(bào)告中有一個(gè)來自于瑞士的研究結(jié)果，它顯示在一些患者群中，使用強(qiáng)生制藥廠的cypher支架比使用taxus支架有更大的長(zhǎng)期血栓風(fēng)險(xiǎn)。

stents are metal sleeves inserted in arteries to keep them propped open after medical procedures to clear blockages.although some are used during heart bypass surgery,most coronary stents are inserted as a follow-up to angioplasty,a less invasive procedure in which the blockage is cleared from inside the artery by inflating a balloon.the balloon and stent are delivered to the heart area via a long catheter inserted into a blood vessel in the patient's thigh.

血管支架是置于動(dòng)脈管內(nèi)的金屬套管，用于在清除血管阻塞醫(yī)學(xué)治療后維持血管暢通。雖然也有一些被用于心臟搭橋手術(shù)，但大多數(shù)心血管支架用于血管成形術(shù)的后續(xù)治療器械，這樣可以使通過給氣球充氣從動(dòng)脈內(nèi)部清除動(dòng)脈阻塞的過程更不易擴(kuò)散。氣球和支架經(jīng)導(dǎo)管通過患者大腿血管置入到心臟區(qū)域。

stents were first used in the 1990's.the original designs were bare metal devices.cypher,introduced in the united states in 2003,and taxus,which was cleared for sale in 2004,are drug-coated devices.the coatings are meant to combat the tendency of arteries to form new blockages,a process called restenosis.

血管支架首先在20世紀(jì)90年代開始使用，最初完全是由金屬制成。cypher于2003年亮相美國(guó)市場(chǎng)，taxus于2004年面市。兩款器械外面都包裹著藥物涂層。這些藥物涂層用于防止再狹窄過程，即動(dòng)脈血管產(chǎn)生新阻塞。

although the drug-coated devices cost more than$2,000 on average,compared with$800 or so for bare metal devices,they rapidly supplanted the older designs in the united states and now account for 85 percent to 90 percent of the market.

盡管這種藥物涂層血管支架平均價(jià)值超過2000美元，比800美元的純金屬器械貴得多，但是這種器械卻在美國(guó)很快取代了老的器械，現(xiàn)在已經(jīng)占有85%到90%的市場(chǎng)份額。

以上是醫(yī)學(xué)教育網(wǎng)小編整理的“醫(yī)學(xué)雙語閱讀：安全問題影響支架生產(chǎn)商”全部?jī)?nèi)容，想了解更多醫(yī)學(xué)英語知識(shí)及內(nèi)容，請(qǐng)點(diǎn)擊醫(yī)學(xué)教育網(wǎng)。